Approved Research This page provides a searchable list of all research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology(UNCST).
Search By Approval Date:
Clear Filter Total: 6,466
Name Title Nationality Approval Date Expiry Date Field of Science/Classification Trial Type Research Type  
William Blackmon
ID: UNCST-2025-R017006
 Consumer Protection Surveys - Uganda
REFNo: SS3650ES

The project aims to:
• Measure consumer protection risks associated with digital financial services (DFS) usage in Uganda
• Track consumer protection risks across two survey rounds
• Create a comparable cross-country analysis (the survey is also carried out in 10 other countries)

 USA 2025-04-02 9:06:12 2028-04-02 Social Science and Humanities Non-Clinical Trial Non-degree Award
Maxensia owor
ID: UNCST-2021-R014003
 An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase: NeoSep1
REFNo: HS5639ES

In Part 2, a secondary objective is to provide a ranking of clinically relevant antibiotic regimens based on other efficacy and safety secondary outcomes, as well as on health economic measures and the potential selection of resistance. The trial data will provide data to inform the balance between efficacy, safety, costs (and cost-effectiveness and equity, using health economic analysis) and propensity for resistance selection (based on microbiology tests) that will influence facility-level and national decision-making about adoption of studied regimens, and potential future inclusion in WHO guidelines.,In Part 2, the primary objective is to provide a ranking of eight different clinically relevant antibiotic regimens for first-line empiric and second-line (after lack of response/deterioration) treatment in terms of 28-day mortality as the primary outcome measure. It will flexibly compare these multiple different relevant treatment regimens to enable the trial to be run in sites worldwide with very different background rates of different pathogens, of resistance and patterns of routine clinical care by randomising each participant to locally relevant antibiotic regimens agreed prior to site initiation. The trial will ensure generalisability by focusing inclusion based on clinical symptoms associated with high mortality risk in the NeoOBS study, which have been developed into a novel neonatal sepsis severity score – the NeoSep Severity Score.,
 Uganda 2025-04-02 9:04:16 2028-04-02 Medical and Health Sciences Clinical Trial Non-degree Award
Gloria Lubega
ID: UNCST-2025-R017180
 A retrospective review of patients admitted with SARS-COV-2 at Entebbe regional referral hospital in Uganda across multiple waves.
REFNo: HS5695ES

I. To evaluate the mortality rate, risk factors associated with mortality and prolonged hospital admission among patients admitted with severe COVID-19 disease at ERRH.
II. To determine the time to discharge of patients admitted with severe COVID-19 disease at ERRH.
III. To describe the characteristics of patients across different age groups admitted with severe COVID-19 at Entebbe Regional Referral Hospital
IV. To describe treatment options offered to patients admitted with severe COVID-19 disease with reference to Uganda MoH and WHO recommended treatment options.
V. To compare characteristics of patients who were vaccinated against COVID-19 admitted with severe disease and unvaccinated patients admitted with severe COVID-19 disease.

 Uganda 2025-04-02 9:01:54 2028-04-02 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Mark Kaddumukasa
ID: UNCST-2020-R001798
 Building a Collaborative Research and Training Platform for HIV and Rheumatic and Musculoskeletal Diseases in Uganda
REFNo: HS5606ES

Objective 1. Establish the Ugandan Registry of RMDs in HIV (GEMINI), to create a foundation for future prospective studies on HIV and RMDs.
Objective 2. In a pilot study, among a subset of participants from GEMINI with both RA and HIV, compared to participants with HIV only and RA only, explore the impact of co-morbid disease status on markers of bone metabolism, bone mineral density, as well as quality of life and functional disability.
Uganda 2025-04-02 9:00:14 2028-04-02 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Sylvia Kusemererwa
ID: UNCST-2019-R001717
 A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises
REFNo: HS5607ES

To assess the efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without
hydroxyurea (HU)/hydroxycarbamide (HC) , on VOC rate in Sickle Cell Disease (SCD) patients aged 12 years and older who experience frequent vaso-occlusive crises (VOCs)
Primary Objective
1. To compare the efficacy of 5 mg/kg of crizanlizumab versus placebo, with or without hydroxyurea/hydroxycarbamide, on the annualized rate of VOCs* that are HCP managed (including VOCs leading to management at a health care facility or those via remote consultation) over the planned 52-week treatment period in SCD patients aged 12 years and older with a history of frequent VOCs (4-12 events in 12 months prior to the screening visit).
Secondary Objectives
1. To compare the efficacy of 5 mg/kg of crizanlizumab versus placebo, with or without
hydroxyurea/hydroxycarbamide, on the annualized rate of all VOCs including VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) and VOCs that are self-managed without recommendations from HCP during the event over the planned 52-week treatment period in SCD patients aged 12 years and older with a history of frequent VOCs (4-12 events in the 12 months prior to the screening visit).
2. To evaluate the annualized rate of VOCs by type of management between treatment arms over the planned 52-week treatment period:
? VOCs that are HCP-managed at a health care facility
? VOCs that are HCP-managed via remote consultation
Page 4 of 18
? VOCs that are self-managed without recommendations from HCP during the event
? VOCs that are HCP-managed via remote consultation or self-managed without recommendations from HCP during the event
 Uganda 2025-04-02 8:58:47 2028-04-02 Medical and Health Sciences Clinical Trial Non-degree Award
View Sort By:

"A prosperous Science and Technology Led Ugandan Society."

NRIMS